Shamash J, et al. - Forty-eight patients with metastatic seminoma were assessed by the researchers to determine the effectiveness of early response in de-escalation of carboplatin monotherapy. Hundred percent of overall survival at 2-years was noted. Although the association was weak, lower stage disease was significantly related to a better metabolic response. With a low incidence of grade III neutropenic sepsis or nausea and vomiting, the regimen was well tolerated. Hence, the authors concluded that carboplatin AUC-10 monotherapy was effective with low toxicity. De-escalation of therapy in high volume disease could be allowed with early changes during positron emission tomography and comparison against combination therapy was warranted.